title: Unilateral taxane-induced onychopathy in a patient with a brain metastasis.
abstract: Chemotherapy using taxanes have been useful in the treatment of several types of solid tumors. Nail abnormalities have been reported primarily with the use of docetaxel, but also with low dose, weekly paclitaxel. We report a patient with 20-nail onycolysis associated with the use of paclitaxel that resolved after stopping the medication and then recurred after the use of docetaxel, but spared all the nails of a paretic hand.
authors.affiliation: Dermatology Department, Ramón y Cajal Hospital, University of Alcalá de Henares, Madrid, Spain.
authors.forename: M
authors.initials: M
authors.lastname: Truchuelo
authors.forename: S
authors.initials: S
authors.lastname: Vano-Galvan
authors.forename: B
authors.initials: B
authors.lastname: Pérez
authors.forename: E
authors.initials: E
authors.lastname: Muñoz-Zato
authors.forename: P
authors.initials: P
authors.lastname: Jaén
mesh_terms: D000911:Antibodies, Monoclonal / Q000008:administration & dosage; D061067:Antibodies, Monoclonal, Humanized; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage / Q000009:adverse effects*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001932:Brain Neoplasms / Q000150:complications / Q000188:drug therapy / Q000556:secondary*; D001943:Breast Neoplasms / Q000188:drug therapy / Q000473:pathology* / Q000532:radiotherapy / Q000601:surgery; D000069287:Capecitabine; D016190:Carboplatin / Q000008:administration & dosage; D003131:Combined Modality Therapy; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives; D000077143:Docetaxel; D017809:Fatal Outcome; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage / Q000031:analogs & derivatives; D006225:Hand / Q000294:innervation; D006801:Humans; D000077341:Lapatinib; D008875:Middle Aged; D054039:Onycholysis / Q000139:chemically induced*; D017239:Paclitaxel / Q000008:administration & dosage; D010291:Paresis / Q000209:etiology; D010523:Peripheral Nervous System Diseases / Q000139:chemically induced*; D011799:Quinazolines / Q000008:administration & dosage; D043823:Taxoids / Q000008:administration & dosage / Q000009:adverse effects*; D000068878:Trastuzumab; D014747:Vinblastine / Q000008:administration & dosage / Q000031:analogs & derivatives; D000077235:Vinorelbine
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000972:Antineoplastic Agents, Phytogenic; D011799:Quinazolines; D043823:Taxoids; D000077341:Lapatinib; D003841:Deoxycytidine; D000077143:Docetaxel; D014747:Vinblastine; D000069287:Capecitabine; D016190:Carboplatin; D000068878:Trastuzumab; D017239:Paclitaxel; D000077235:Vinorelbine; D005472:Fluorouracil